Britain and America have signed a major trade agreement that will ensure zero tariffs on UK pharmaceutical exports being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to boost expenditure on medicines through the NHS. This pledge secures that tariffs on these key goods will be held at zero for a timeframe of the next three years.
This deal is in response to earlier warnings to significantly raise tariffs on branded pharmaceutical imports, with figures floated up to double the cost.
"This agreement between the Britain strengthens the worldwide climate for innovative medicines and introduces long-overdue equity to American-British medicine commerce," an announcement noted.
Trade Importance
Drugs are one of the the United Kingdom's biggest exports to the America, which is easily the primary market for large companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period leading up to last September, the UK shipped drugs totaling over eleven billion pounds to the US. This amount made up a significant portion of total UK exports in that span.
"This deal safeguards employment, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Detailed British Pledges
The pact involves several notable commitments from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates topped 20%.
Broader Context
This agreement takes place against a long-running tension between the sector and the ministers over spending levels and regulatory access.
These tensions were intensified by assertions that American consumers were charged several times more for the same drugs than patients in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or cancelled, while substantial funding commitments have been directed toward projects in the United States.
One official stated that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had declined as a percentage of its overall budget over the previous ten-year period.
